FMED ETF Composition
General Overview
The fund normally invests at least 80% of assets in securities of disruptive medicine companies. Fidelity's disruptive strategies seek to identify innovative developments that could signal new directions for delivering products and services to customers. Generally, these companies have or are developing new or unconventional ways of doing business that could disrupt and displace incumbents over time. The fund is non-diversified.
| Sector & Industry | Financial Services / Asset Management |
| IPO date | June 12, 2023 |
FMED Latest News
|
|
|
|
|
|
|
|
|
|
| Other Identifiers | |
|---|---|
| CIK | None |
| ISIN | US3160921470 |
| CUSIP | 316092147 |
| Open | 23.75 |
| Previous Close | 23.6 |
| Volume | 10.68 Thou. |
| Average Volume | 6.72 Thou. |
| Day’s Range | 23.58 – 23.82 |
| 52 Week Range | 20.69-26.79 |
| MA (50) | 23.66236 |
| MA (200) | 24.787 |
| Market Cap | 49.24 Mil. |
| Shares Out. | 2.07 Mil. |
| Earnings Date | |
| Beta | |
| Last Dividend | |
| EPS | |
| PE | |
